Looking for signs of liver cancer in people with cirrhosis after hepatitis C treatment
Studies factors linked to hepatocellular carcinoma in cirrhosis patients after hepatitis C treatment.
Plain-language title generated from the registry record
Registry title: Predictors of HCC in Post-HCV Cirrhotic Patients After SVR
Key facts
- Where
- Sohag, EgyptSee the site
Where in Egypt
- Faculty of Medicine, Sohag UnivesitySohag, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sohag University
- Trial code
- NCT07097870
- Record updated
- 5 August 2025
- Original description
This study aims to identify clinical and laboratory factors that predict the occurrence of hepatocellular carcinoma (HCC) in Egyptian cirrhotic patients after achieving a sustained virologic response (SVR) to hepatitis C virus (HCV) treatment. This is a retrospective, two-center, case-control study that will include 132 cases and 264 controls. Variables to be analyzed include demographics, liver disease status, metabolic comorbidities, lifestyle factors, medications, as well as laboratory parameters and non-invasive scoring systems.Read full original descriptionShow less
Study of Clinical and Laboratory Predictors of Hepatocellular Carcinoma in Post-HCV Cirrhotic Patients After Sustained Virologic Response.
This study aims to identify clinical and laboratory factors that predict the occurrence of hepatocellular carcinoma (HCC) in Egyptian cirrhotic patients after achieving a sustained virologic response (SVR) to hepatitis C virus (HCV) treatment. This is a retrospective, two-center, case-control study that will include 132 cases and 264 controls. Variables to be analyzed include demographics, liver disease status, metabolic comorbidities, lifestyle factors, medications, as well as laboratory parameters and non-invasive scoring systems.
Inclusion: for cases:; age ≥ 18 y; HCV related cirrhosis; SVR12 after DAA; radiologic or histologic HCC diagnosis ≤30 Jun 2025; for controls: As above plus, ≥36 months post SVR without HCC.
Exclusion: for cases:; non HCV cirrhosis or combined HCV-HBV cirrhosis; HCC <6 months before SVR; concomitant cholangiocarcinoma; for controls: Same as cases, plus, loss to follow up before 36 months.